Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mainstay Lands $108M To Support Launch Of ReActiv8 Back Pain Device

Executive Summary

The company has begun the US launch of the ReActiv8 implantable neurostimulator for treating low back pain in the US while expanding commercialization in Australia and Europe.

You may also be interested in...



Financing Quarterly Statistics: Q1 Highlights Include 3 Medtech And 7 IVD IPOs

To open the year, medical device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $7bn.

Trial Results Fail To Support Mainstay Medical's Neuromodulation Device

Mainstay Medical says it will move forward with a US PMA application for its ReActiv8 neuromodulation therapy for chronic back pain even though the ReActiv8 clinical trial failed to reach its primary endpoint.

Podcast Special: J&J's Andrie Leday Addresses ASC Market With Customized Approach

In this special podcast from Medtech Insight, editor Reed Miller talked to Andrie Leday, the US vice president for ambulatory surgery centers (ASCs) at Johnson & Johnson/DePuy Synthes. Leday's group is dedicated to creating a new "ecosystem" around DePuy Synthes broad range of orthopedic implants and tools to meet the demand of an aging population.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel